ASX-Dividend-Report-Banner

Expediting R&D Digitization for Life Sciences, ArisGlobal Introduces LifeSphere® NavaX™ - The Next-Generation Cognitive Computing Engine

December 15, 2023 07:01 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Expediting R&D Digitization for Life Sciences, ArisGlobal Introduces LifeSphere® NavaX™ - The Next-Generation Cognitive Computing Engine
Image source: Kalkine Media

NavaX will revolutionize the end-to-end Research and Development processes with the latest advanced technologies

BOSTON, Dec. 15, 2023 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, has today launched LifeSphere NavaX, a cutting-edge cognitive computing engine to expedite R&D IT Digitization by leveraging advanced technologies including Large Language Models (LLM) and Generative AI (Gen AI).

LifeSphere is the industry's leading R&D compliance platform. In 2018, the company introduced LifeSphere MultiVigilance (LSMV), a platform for individual case safety report (ICSR) intake. LSMV was powered by LifeSphere Nava (v1) – at introduction, LifeSphere Nava offered the latest robotic process automation and cognitive computing technologies, including natural language processing (NLP) and machine learning (ML), to transform pharmacovigilance (PV) activities.

Today, LifeSphere NavaX includes next-generation technologies that will bring comprehensive efficiency gains across the end-to-end PV and regulatory processes. Organizations leveraging LifeSphere NavaX will benefit from the latest developments from ArisGlobal, including:

  • Proactive Signal Detection (with the use of Real-World Data),
  • Generative AI (Gen AI), and
  • Large Language Models (LLM) features and functionality

Half (49%) of all Life Sciences organizations have cited a desire to deploy Gen AI in the next 12 months, in a survey conducted for the Gartner 2024 CIO Agenda, with 15% pointing to deployment within 12-24 months; only 8% having deployed the technology already. The growing appetite for smart process automation reflects the soaring pressure on Life Sciences companies and their PV and Regulatory operations to be more agile and efficient, uphold the highest standards of patient safety while improving quality and compliance.

Aman Wasan, CEO of ArisGlobal, said: "Our vision is to transform the R&D IT ecosystem with advanced technology. NavaX will help global pharmaceutical, biotech, and health authorities achieve greater value leveraging cutting-edge technology. With more than 30 years of experience in the Life Sciences industry,  ArisGlobal team will work closely with each customer to unlock exceptional benefits with NavaX."

Ann-Marie Orange, CIO & Global Head of R&D at ArisGlobal said, "Companies are facing monumental challenges including increasing case volume, balancing the need to elevate drug safety and efficacy while containing rising R&D costs, responding to regulatory complexity, and a growing pressure to harness big data and analytics. Compounding these challenges, there remain inefficient legacy IT systems, workflows, and processes, along with budget and resource constraints." Orange adds, "Our LifeSphere platform codifies decades of R&D and compliance expertise, making it available to our customers. LifeSphere NavaX builds on our proven platform, allowing the Life Sciences industry access to digital innovations that are driving the world forward."

NavaX Technology Highlights

  • NavaX is scalable and customizable; allows PV and Regulatory teams to remain in control and set their own pace based on their objectives, goals, and timing.
  • NavaX supercharges LifeSphere solutions, which seamlessly integrate with third-party systems to ensure a smooth transition to a more intelligent and automated future.
  • NavaX is built and enhanced with continuous inputs from pharmaceutical and regulatory partners, with the highest standards within the establishment of robust governance frameworks and compliance standards.

Today, more than 500 global pharmaceutical and biotech companies (90% of the Top 10 pharma brands) leverage LifeSphere, ArisGlobal's open R&D and compliance platform transforming the way Life Science companies develop breakthroughs and bring new patient treatments to market, faster. Current LifeSphere platform customers have achieved exceptional process efficiency gains and cost savings. By powering next-generation digital process innovation, NavaX will supercharge operational efficiency, drive even faster time to insights, and ensure greater compliance.

Learn more about LifeSphere NavaX, here.

About ArisGlobal
ArisGlobal is the creator of LifeSphere, a market leader in global patient treatment technology solutions that is transforming the way today's most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn and www.arisglobal.com.

Logo - https://mma.prnasia.com/media2/1510670/ArisGlobal_Logo.jpg?p=medium600


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.